Giant Gastrointestinal Stromal Tumor with Remarkable Preoperative Response to Imatinib Mesylate

The development of IM was featured on the cover of Time in May 2001, was touted as a revolutionary therapeutic agent for chronic myelogenous leukemia, and was later found to be effective in the control of GIS tumors. [...] its indication for use has been for patients with malignant metastatic or unr...

Full description

Saved in:
Bibliographic Details
Published in:The American surgeon 2010-08, Vol.76 (8), p.903-904
Main Authors: STOKES, Allen, HERNDON, Mark D, CONFORTI, Arnold M
Format: Article
Language:English
Subjects:
Antineoplastic Agents - therapeutic use
Benzamides
Biological and medical sciences
Gastroenterology. Liver. Pancreas. Abdomen
Gastrointestinal Stromal Tumors - drug therapy
General aspects
Humans
Imatinib Mesylate
Male
Medical sciences
Medical treatment
Middle Aged
Piperazines - therapeutic use
Pyrimidines - therapeutic use
Stomach. Duodenum. Small intestine. Colon. Rectum. Anus
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The development of IM was featured on the cover of Time in May 2001, was touted as a revolutionary therapeutic agent for chronic myelogenous leukemia, and was later found to be effective in the control of GIS tumors. [...] its indication for use has been for patients with malignant metastatic or unresectable disease.1 Eisenberg et al. report that more than 80% of malignant metastatic or inoperable GIST have achieved a decrease in tumor burden of 50% or more (partial response) or had no disease progression. . .
ISSN:0003-1348
1555-9823
DOI:10.1177/000313481007600840